PSNL · NASDAQ
Personalis, Inc.
$15.85 +0.03 (+0.19%)
Company overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. Its NeXT Platform provides data analysis for tumors and their immune microenvironment from a single limited tissue or plasma sample. The company also offers ImmunoID Next for tumor profiling from tissue, NeXT Liquid Biopsy for tumor profiling from plasma, NeXT Personal for personalized tumor tracking, NeXT Dx Test as a genomic cancer profiling test enabling composite biomarkers, and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The ACE platform supports clinical and therapeutic applications including neoantigen prediction, biomarker identification, and novel drug target selection.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $1.7B
- Employees
- 228
- Headquarters
- Fremont, CA
- Website
- personalis.com
- CEO
- Christopher Hall
- Listed
- June 20, 2019
- P/E
- -15.54
- Dividend yield
- 0.00%
Company financials
- Revenue
- $64.5M
- Gross profit
- $8.9M
- Operating income
- -$103M
- EBITDA
- -$87.7M
- Net income
- -$95.6M
- EPS
- -$1.02
- Total assets
- $325M
- Total debt
- $31M
- Gross margin
- 13.72%
- Net margin
- -148.11%
- Earnings yield
- -6.44%
PSNL
1D
NASDAQ
O15.77H15.89L15.74C15.85+0.03 (+0.19%)Vol302.55K